Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $59.9 million versus the consensus estimate of $61.7 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $250-260 million, versus the consensus of $274.4 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Activist Jana Partners takes 6.3% stake in Alkami Technology, urges sale
• FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing